Burzynski Sanctioned by Texas Medical Board | Pocketmags.com

Shopping Cart -

Your cart is currently empty.
Upgrade to today
for only an extra Cxx.xx

You get:

plus This issue of xxxxxxxxxxx.
plus Instant access to the latest issue of 300+ of our top selling titles.
plus Unlimited access to 27000+ back issues
plus No contract or commitment. If you decide that PocketmagsPlus is not for you, you can cancel your monthly subscription online at any time. Auto-renews at $14.99 per month, unless cancelled.
Upgrade Now for $14.99 Learn more
This website use cookies and similar technologies to improve the site and to provide customised content and advertising. By using this site, you agree to this use. To learn more, including how to change your cookie settings, please view our Cookie Policy
Pocketmags Digital Magazines
Pocketmags Digital Magazines
   You are currently viewing the Australia version of the site.
Would you like to switch to your local site?
Read anywhere Read anywhere
Ways to pay Pocketmags Payment Types
Trusted site
At Pocketmags you get
Secure Billing
Great Offers
Web & App Reader
Gifting Options
Loyalty Points

Burzynski Sanctioned by Texas Medical Board

On March 3, 2017, the Texas Medical Board sanctioned Houston internist Stanislaw Burzynski for over a hundred violations related to his cancer clinic. However, despite these sanctions, Burzynski will be allowed to keep his medical license and continue to practice on patients.

For decades, Burzynski has peddled a chemotherapy he calls “antineo plastons” (ANP) under the auspices of dubious FDA-sanctioned clinical trials (see “Stanislaw Burzynski: Four Decades of an Unproven Cancer Cure” and “Skeptic Activists Fighting for Burzynski Cancer Patients,” SI March/April 2014).

Burzynski sells a chemotherapy of the metabolic derivatives of sodium phenylbutyrate, a urea cycle drug that he also produces at his Houston manufacturing facility. Antineoplastons are typically administered intrave nously under clinical trial protocols and frequently under compassionate care exemptions. In recent years, however, Burzynski has taken to selling something he calls “personalized gene targeted therapy,” which is a low-dose chemotherapy cocktail (based on a genetic test) plus sodium phenyl butyrate. The theory behind antineoplaston therapy, according to Burzynski, is that cancer patients have lower levels of these peptides and amino acids in their blood and urine and that replacing them can cure cancer.

Purchase options below
Find the complete article and many more in this issue of Skeptical Inquirer - July August 2017
If you own the issue, Login to read the full article now.
Single Issue - July August 2017
Or 449 points
Getting free sample issues is easy, but we need to add it to an account to read, so please follow the instructions to read your free issue today.
Email Address
Annual Digital Subscription
Only $ 4.33 per issue
Or 2599 points

View Issues

About Skeptical Inquirer

Fire-Breathing Dinosaurs? Physics, Fossils, and Functional Morphology vs. Pseudoscience JonBenet Murder Mystery Solved? (Not by Psychics) An Investigation of the Missing411 Conspiracy